{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:01:43Z","timestamp":1789664503329,"version":"4.0.1"},"reference-count":56,"publisher":"The University of Occupational and Environmental Health, Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J UOEH"],"published-print":{"date-parts":[[2025,6,1]]},"DOI":"10.7888\/juoeh.47.95","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T22:11:55Z","timestamp":1748729515000},"page":"95-103","source":"Crossref","is-referenced-by-count":7,"title":["Comorbidity of Major Depression and Type 2 Diabetes Mellitus: Epidemiology, Pathophysiology, and Treatment Approaches","\u3046\u3064\u75c5\u30682\u578b\u7cd6\u5c3f\u75c5\u306e\u4f75\u767a\u7387\uff1a\u75ab\u5b66\uff0c\u75c5\u7406\uff0c\u6cbb\u7642\u30a2\u30d7\u30ed\u30fc\u30c1"],"prefix":"10.7888","volume":"47","author":[{"given":"Reiji","family":"YOSHIMURA","sequence":"first","affiliation":[{"name":"Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"WATANABE","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4637","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Moulton CD, Pickup JC &amp; Ismail K (2015): The link between depression and diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol 3 (6): 461\u2013471","DOI":"10.1016\/S2213-8587(15)00134-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. van Gennip ACE, Schram MT, Kohler S <i>et al<\/i> (2023): Association of type 2 diabetes according to the number of risk factors within the recommended range with incidence of major depression and clinically relevant depressive symptoms: a prospective analysis. Lancet Healthy Longev 4 (2): e63\u2013e71","DOI":"10.1016\/S2666-7568(22)00291-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tabak AG, Akbaraly TN, Batty GD &amp; Kivimaki M (2014): Depression and type 2 diabetes: a causal association? Lancet Diabetes Endocrinol 2 (3): 236\u2013245","DOI":"10.1016\/S2213-8587(13)70139-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sartorius N (2018): Depression and diabetes. Dialogues Clin Neurosci 20 (1): 47\u201352","DOI":"10.31887\/DCNS.2018.20.1\/nsartorius"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Anderson RJ, Freedland KE, Clouse RE &amp; Lustman PJ (2001): The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24 (6): 1069\u20131078","DOI":"10.2337\/diacare.24.6.1069"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Roy T &amp; Lloyd CE (2012): Epidemiology of depression and diabetes: a systematic review. J Affect Disord 142 Suppl: S8\u201321","DOI":"10.1016\/S0165-0327(12)70004-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Naskar S, Victor R &amp; Nath K (2017): Depression in diabetes mellitus-A comprehensive systematic review of literature from an Indian perspective. Asian J psychiatr 27: 85\u2013100","DOI":"10.1016\/j.ajp.2017.02.018"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Alfadul H, Sabico S &amp; Al-Daghri NM (2022): The role of interleukin-1beta in type 2 diabetes mellitus: A systematic review and meta-analysis. Front Endocrinol (Lausanne) 13: 901616","DOI":"10.3389\/fendo.2022.901616"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chen YL, Qiao YC, Pan YH <i>et al<\/i> (2017): Correlation between serum interleukin-6 level and type 1 diabetes mellitus: A systematic review and meta-analysis. Cytokine 94: 14\u201320","DOI":"10.1016\/j.cyto.2017.01.002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ni J, Wang Y, Zhu J, Zheng T, Yu J &amp; Xiong Y (2022): Interleukin-10 levels and risk of gestational diabetes mellitus: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 35 (25): 7609\u20137616","DOI":"10.1080\/14767058.2021.1957820"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H &amp; Kivimaki M (2015): Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 49: 206\u2013215","DOI":"10.1016\/j.bbi.2015.06.001"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Dowlati Y, Herrmann N, Swardfager W <i>et al<\/i> (2010): A meta-analysis of cytokines in major depression. Biol Psychiatry 67 (5): 446\u2013457","DOI":"10.1016\/j.biopsych.2009.09.033"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Eyre HA, Air T, Pradhan A <i>et al<\/i> (2016): A meta-analysis of chemokines in major depression. Prog Neuropsychopharmacol Biol Psychiatry 68: 1\u20138","DOI":"10.1016\/j.pnpbp.2016.02.006"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Islam MR, Sohan M, Daria S <i>et al<\/i> (2023): Evaluation of inflammatory cytokines in drug-naive major depressive disorder: A systematic review and meta-analysis. Int J Immunopathol Pharmacol 37: 3946320231198828","DOI":"10.1177\/03946320231198828"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Jadhav KK, Daouk J, Kurkinen K <i>et al<\/i> (2025): Blood cytokines in major depressive disorder in drug-naive adolescents: A systematic review and meta-analysis. J Affect Disord 372: 48\u201355","DOI":"10.1016\/j.jad.2024.11.071"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Vrshek-Schallhorn S, Doane LD, Mineka S, Zinbarg RE, Craske MG &amp; Adam EK (2013): The cortisol awakening response predicts major depression: predictive stability over a 4-year follow-up and effect of depression history. Psychol Med 43 (3): 483\u2013493","DOI":"10.1017\/S0033291712001213"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Herbert J (2013): Cortisol and depression: three questions for psychiatry. Psychol Med 43 (3): 449\u2013469","DOI":"10.1017\/S0033291712000955"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Fiksdal A, Hanlin L, Kuras Y <i>et al<\/i> (2019): Associations between symptoms of depression and anxiety and cortisol responses to and recovery from acute stress. Psychoneuroendocrinology 102: 44\u201352","DOI":"10.1016\/j.psyneuen.2018.11.035"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lederbogen F, Hummel J, Fademrecht C <i>et al<\/i> (2011): Flattened circadian cortisol rhythm in type 2 diabetes. Exp Clin Endocrinol Diabetes 119 (9): 573\u2013575","DOI":"10.1055\/s-0031-1275288"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Joseph JJ &amp; Golden SH (2017): Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus. Ann N Y Acad Sci 1391 (1): 20\u201334","DOI":"10.1111\/nyas.13217"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mehdi S, Wani SUD, Krishna KL, Kinattingal N &amp; Roohi TF (2023): A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation. Biochem Biophys Rep 36: 101571","DOI":"10.1016\/j.bbrep.2023.101571"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Darenskaya MA, Kolesnikova LI &amp; Kolesnikov SI (2021): Oxidative stress: Pathogenetic role in diabetes mellitus and its complications and therapeutic approaches to correction. Bull Exp Biol Med 171 (2): 179\u2013189","DOI":"10.1007\/s10517-021-05191-7"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Yaribeygi H, Sathyapalan T, Atkin SL &amp; Sahebkar A (2020): Molecular mechanisms linking oxidative stress and diabetes mellitus. Oxid Med Cell Longev 2020: 8609213","DOI":"10.1155\/2020\/8609213"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ighodaro OM (2018): Molecular pathways associated with oxidative stress in diabetes mellitus. Biomed Pharmacother 108: 656\u2013662","DOI":"10.1016\/j.biopha.2018.09.058"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kokkinopoulou I, Diakoumi A &amp; Moutsatsou P (2021): Glucocorticoid receptor signaling in diabetes. Int J Mol Sci 22 (20): 11173","DOI":"10.3390\/ijms222011173"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Singh A, Kukreti R, Saso L &amp; Kukreti S (2022): Mechanistic insight into oxidative stress-triggered signaling pathways and type 2 diabetes. Molecules 27 (3): 950","DOI":"10.3390\/molecules27030950"},{"key":"27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12933-023-01965-7","volume":"22","year":"2023","unstructured":"27. An Y, Xu B-t, Wan S-r <i>et al<\/i> (2023): The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction. Cardiovascular Diabetology 22: 237","journal-title":"Cardiovascular Diabetology","ISSN":"https:\/\/id.crossref.org\/issn\/1475-2840","issn-type":"print"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Bhatt S, Nagappa AN &amp; Patil CR (2020): Role of oxidative stress in depression. Drug Discov Today 25 (7): 1270\u20131276","DOI":"10.1016\/j.drudis.2020.05.001"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Correia AS &amp; Vale N (2022): Tryptophan metabolism in depression: A narrative review with a focus on serotonin and kynurenine pathways. Int J Mol Sci 23 (15): 8493","DOI":"10.3390\/ijms23158493"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Muneer A (2020): kynurenine pathway of tryptophan metabolism in neuropsychiatric disorders: Pathophysiologic and therapeutic considerations. Clin Psychopharmacol Neurosci 18 (4): 507\u2013526","DOI":"10.9758\/cpn.2020.18.4.507"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Sipahi H, Mat AF, Ozhan Y &amp; Aydin A (2023): The interrelation between oxidative stress, depression and inflammation through the kynurenine pathway. Curr Top Med Chem 23 (6): 415\u2013425","DOI":"10.2174\/1568026623666221223111309"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Koziel K &amp; Urbanska EM (2023): Kynurenine pathway in diabetes mellitus-novel pharmacological target? Cells 12 (3): 460","DOI":"10.3390\/cells12030460"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Gao J, Yang T, Song B <i>et al<\/i> (2023): Abnormal tryptophan catabolism in diabetes mellitus and its complications: Opportunities and challenges. Biomed Pharmacother 166: 115395","DOI":"10.1016\/j.biopha.2023.115395"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Badawy AA, Dawood S &amp; Bano S (2023): Kynurenine pathway of tryptophan metabolism in pathophysiology and therapy of major depressive disorder. World J Psychiatry 13 (4): 141\u2013148","DOI":"10.5498\/wjp.v13.i4.141"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Okamoto N, Hoshikawa T, Honma Y <i>et al<\/i> (2024): Effect modification of tumor necrosis factor-alpha on the kynurenine and serotonin pathways in major depressive disorder on type 2 diabetes mellitus. Eur Arch Psychiatry Clin Neurosci 274 (7): 1697\u20131707","DOI":"10.1007\/s00406-023-01713-8"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S &amp; Fadini GP (2011): Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 34 Suppl 2 (Suppl 2): S285\u2013290","DOI":"10.2337\/dc11-s239"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Simo R, Sundstrom JM &amp; Antonetti DA (2014): Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care 37 (4): 893\u2013899","DOI":"10.2337\/dc13-2002"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Jiang Y, Li J, Zhang J &amp; Chen S (2023): Serum VEGF as a predictive marker of glycemic control and diabetic nephropathy in Chinese older adults with type 2 diabetes mellitus. Front Endocrinol (Lausanne) 14: 1274025","DOI":"10.3389\/fendo.2023.1274025"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Shim JW &amp; Madsen JR (2018): VEGF Signaling in Neurological Disorders. Int J Mol Sci 19 (1): 275","DOI":"10.3390\/ijms19010275"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Tseng PT, Cheng YS, Chen YW, Wu CK &amp; Lin PY (2015): Increased levels of vascular endothelial growth factor in patients with major depressive disorder: A meta-analysis. Eur Neuropsychopharmacol 25 (10): 1622\u20131630","DOI":"10.1016\/j.euroneuro.2015.06.001"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Xie T, Stathopoulou MG, de Andres F <i>et al<\/i> (2017): VEGF-related polymorphisms identified by GWAS and risk for major depression. Transl Psychiatry 7 (3): e1055","DOI":"10.1038\/tp.2017.36"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Nguyen L, Kakeda S, Katsuki A <i>et al<\/i> (2019): Relationship between VEGF-related gene polymorphisms and brain morphology in treatment-naive patients with first-episode major depressive disorder. Eur Arch Psychiatry Clin Neurosci 269 (7): 785\u2013794","DOI":"10.1007\/s00406-018-0953-8"},{"key":"43","unstructured":"43. Yoshimura R, Okamoto N &amp; Ikenouchi A (2022): Effects of paroxetine on plasma levels of vascular endothelial growth factor in patients with major depression. Psychiatr Danub 34 (3): 533\u2013534"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Kim Y, Park JE, Lee BW, Jung CH &amp; Park DA (2019): Comparative effectiveness of telemonitoring versus usual care for type 2 diabetes: A systematic review and meta-analysis. J Telemed Telecare 25 (10): 587\u2013601","DOI":"10.1177\/1357633X18782599"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Garcia-Ulloa AC, Cardenas-Fragoso JL, Hernandez-Juarez D <i>et al<\/i> (2024): A case study on the implementation of quality and comprehensive indicators set in routine diabetes care. Arch Public Health 82 (1): 121","DOI":"10.1186\/s13690-024-01348-8"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Katon WJ, Lin EH, Von Korff M <i>et al<\/i> (2010): Collaborative care for patients with depression and chronic illnesses. N Engl J Med 363 (27): 2611\u20132620","DOI":"10.1056\/NEJMoa1003955"},{"key":"47","unstructured":"47. National Institute for Health and Care Excellence (NICE) (2018): Guidelines on Depression. https:\/\/www.nice.org.uk (accessed April 25, 2025)"},{"key":"48","unstructured":"48. American Psychiatric Association (APA) (2019): Practice Guideline for the Treatment of Patients with Major Depressive Disorder. https:\/\/www.psychiatry.org (accessed April 25, 2025)"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Roopan S &amp; Larsen ER (2017): Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review. Acta Neuropsychiatr 29 (3): 127\u2013139","DOI":"10.1017\/neu.2016.54"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Kohler-Forsberg O, C NL, Hjorthoj C, Nordentoft M, Mors O &amp; Benros ME (2019): Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand 139 (5): 404\u2013419","DOI":"10.1111\/acps.13016"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Hang X, Zhang Y, Li J <i>et al<\/i> (2021): Comparative efficacy and acceptability of anti-inflammatory agents on major depressive disorder: A Network meta-analysis. Front Pharmacol 12: 691200","DOI":"10.3389\/fphar.2021.691200"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Du Y, Dou Y, Wang M <i>et al<\/i> (2024): Efficacy and acceptability of anti-inflammatory agents in major depressive disorder: a systematic review and meta-analysis. Front Psychiatry 15: 1407529","DOI":"10.3389\/fpsyt.2024.1407529"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Husain MI, Strawbridge R, Stokes PR &amp; Young AH (2017): Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis. J Psychopharmacol 31 (9): 1137\u20131148","DOI":"10.1177\/0269881117725711"},{"key":"54","doi-asserted-by":"publisher","unstructured":"54. Safren SA, Gonzalez JS, Wexler DJ <i>et al<\/i> (2014): A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with uncontrolled type 2 diabetes. Diabetes Care 37 (3): 625\u2013633","DOI":"10.2337\/dc13-0816"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Newby J, Robins L, Wilhelm K <i>et al<\/i> (2017): Web-based cognitive behavior therapy for depression in people with diabetes mellitus: A randomized controlled trial. J Med Internet Res 19 (5): e157","DOI":"10.2196\/jmir.7274"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. van der Feltz-Cornelis C, Allen SF, Holt RIG, Roberts R, Nouwen A &amp; Sartorius N (2021): Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: Systematic review and meta-analysis. Brain Behav 11 (2): e01981","DOI":"10.1002\/brb3.1981"}],"container-title":["Journal of UOEH"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/juoeh\/47\/2\/47_95\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:39:35Z","timestamp":1749271175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/juoeh\/47\/2\/47_95\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.7888\/juoeh.47.95","relation":{},"ISSN":["0387-821X","2187-2864"],"issn-type":[{"value":"0387-821X","type":"print"},{"value":"2187-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}